Revah joins Genethon as ceo

Genethon, a biotherapy research centre created by the French Muscular Dystrophy Association (AFM), has appointed Frederic Revah as chief executive.

Genethon, a biotherapy research centre created by the French Muscular Dystrophy Association (AFM), has appointed Frederic Revah as chief executive.

Revah brings more than 20 years' experience in the pharmaceutical and biotech industries and academic research to the job.

Immediately prior to joining Genethon, Revah had been chief executive of the oncology start-up Sepal Pharma since 2008. Before that, he was vice president, Drug Discovery, and chief scientific officer of Cerep from 1999 to 2007 and chief executive of its oncology subsidiary.




You may also like

Research & Development

Gene therapy centre to open in France next year

Genethon BioProd to produce 20 clinical batches of gene therapy products a year
Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Research & Development

Almirall advances etherna’s mRNA/LNP therapy LAD116 into IND-enabling studies

Almirall has selected LAD116, developed using etherna's intratumoral mRNA/LNP platform, for IND-enabling studies in non-melanoma skin cancer, marking a key milestone toward GMP manufacturing and Phase I clinical trials
Subscribe now